WO2000041693A3 - Compositions having improved delivery of actives - Google Patents

Compositions having improved delivery of actives Download PDF

Info

Publication number
WO2000041693A3
WO2000041693A3 PCT/US2000/000575 US0000575W WO0041693A3 WO 2000041693 A3 WO2000041693 A3 WO 2000041693A3 US 0000575 W US0000575 W US 0000575W WO 0041693 A3 WO0041693 A3 WO 0041693A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
liquid
actives
improved delivery
pharmaceutical actives
Prior art date
Application number
PCT/US2000/000575
Other languages
French (fr)
Other versions
WO2000041693A2 (en
Inventor
Douglas Joseph Dobrozsi
Jerry William Ii Hayes
Kishor Jivanlal Desai
Brian James Robbins
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority to EP00908243A priority Critical patent/EP1140093A2/en
Priority to CA2356881A priority patent/CA2356881C/en
Priority to JP2000593304A priority patent/JP2002534463A/en
Priority to AU29627/00A priority patent/AU762366B2/en
Priority to BR0007445-4A priority patent/BR0007445A/en
Publication of WO2000041693A2 publication Critical patent/WO2000041693A2/en
Publication of WO2000041693A3 publication Critical patent/WO2000041693A3/en
Priority to NO20013442A priority patent/NO20013442L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Abstract

The present invention pertains to compositions having improved delivery of pharmaceutical actives. These compositions comprise pharmaceutical actives in an anhydrous solvent. These compositions may take the form of liquid elixirs placed into the mouth and eventually swallowed, or can be delivered via liquid-filled drops, metered liquid dosing devices, atomizers and liquid-releasing, edible capsules.
PCT/US2000/000575 1999-01-11 2000-01-10 Compositions having improved delivery of actives WO2000041693A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP00908243A EP1140093A2 (en) 1999-01-11 2000-01-10 Compositions having improved delivery of actives
CA2356881A CA2356881C (en) 1999-01-11 2000-01-10 Compositions having improved delivery of actives
JP2000593304A JP2002534463A (en) 1999-01-11 2000-01-10 COMPOSITIONS WITH IMPROVED ACTIVITY OF ACTIVATORS
AU29627/00A AU762366B2 (en) 1999-01-11 2000-01-10 Compositions having improved delivery of actives
BR0007445-4A BR0007445A (en) 1999-01-11 2000-01-10 Compositions having improved supply of active ingredients
NO20013442A NO20013442L (en) 1999-01-11 2001-07-11 Compositions which provide an improved delivery of active substances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11537899P 1999-01-11 1999-01-11
US60/115,378 1999-01-11

Publications (2)

Publication Number Publication Date
WO2000041693A2 WO2000041693A2 (en) 2000-07-20
WO2000041693A3 true WO2000041693A3 (en) 2000-11-30

Family

ID=22361013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000575 WO2000041693A2 (en) 1999-01-11 2000-01-10 Compositions having improved delivery of actives

Country Status (15)

Country Link
US (1) US6846495B2 (en)
EP (1) EP1140093A2 (en)
JP (1) JP2002534463A (en)
KR (1) KR100511730B1 (en)
CN (1) CN1203854C (en)
AU (1) AU762366B2 (en)
BR (1) BR0007445A (en)
CA (1) CA2356881C (en)
CO (1) CO5270007A1 (en)
CZ (1) CZ20012491A3 (en)
HU (1) HUP0105021A3 (en)
NO (1) NO20013442L (en)
PE (1) PE20001415A1 (en)
TR (1) TR200101927T2 (en)
WO (1) WO2000041693A2 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5599961B2 (en) * 2000-03-09 2014-10-01 ジーダブリュー・ファーマ・リミテッド Pharmaceutical composition
WO2002015900A1 (en) * 2000-08-25 2002-02-28 Kowa Company, Ltd. Ibuprofen solutions for capsule-filling and capsule prepartions
US7138133B2 (en) * 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
LT2486942T (en) 2004-11-24 2019-01-25 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
ES2392097T3 (en) * 2005-02-01 2012-12-04 Troikaa Pharmaceuticals Ltd. Injectable preparations of diclofenac and its pharmaceutically acceptable salts
MX2008012523A (en) * 2006-04-05 2008-10-14 Cadbury Adams Usa Llc Calcium phosphate complex in acid containing chewing gum.
RU2421207C2 (en) 2006-04-05 2011-06-20 КЭДБЕРИ АДАМС ЮЭсЭй ЛЛС Oral composition for improving subsurface remineralisation of denal enamel in mammal
RU2405371C2 (en) * 2006-06-29 2010-12-10 КЭДБЕРИ АДАМС ЮЭсЭй ЛЛС Chain-drive cutting machine for continuous formating of chewing gum with central filler
ES2704409T5 (en) * 2007-07-27 2022-03-25 Intercontinental Great Brands Llc Method and apparatus for processing confectionery
DE102007000521A1 (en) * 2007-10-18 2009-04-23 Renate Conrad cough preparation
ES2465227T3 (en) † 2008-02-08 2014-06-05 The Procter & Gamble Company Process to manufacture a water soluble bag
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
AU2013257706A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
JP6202287B2 (en) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of inflammatory bowel disease
JP2015518854A (en) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of multiple sclerosis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
GB201215988D0 (en) * 2012-09-07 2012-10-24 Reckitt Benckiser Healthcare Int Ltd Pharmaceutical compositions comprising flurbiprofen
CN104364231A (en) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US11179433B2 (en) * 2014-12-12 2021-11-23 Ari Healthcare Pvt. Ltd. Mouth freshener
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
US11234897B2 (en) * 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
EP3793535A1 (en) 2018-05-16 2021-03-24 Bayer Healthcare LLC High concentration suspension formulation for cold and flu soft gel capsule medications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295941A2 (en) * 1987-06-19 1988-12-21 ELAN CORPORATION, Plc Liquid suspension for oral administration
WO1993000072A1 (en) * 1991-06-27 1993-01-07 Richardson Vicks, Inc. Process for solubilizing difficultly soluble pharmaceutical actives
WO1994018970A1 (en) * 1993-02-18 1994-09-01 Warner-Lambert Company Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents
WO1995004527A1 (en) * 1993-08-05 1995-02-16 R.P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125920C (en) * 1960-12-28
US4136163A (en) 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
CA1027347A (en) 1972-07-20 1978-03-07 David G. Rowsell Compounds having a physiological cooling effect and compositions containing them
SE7812207L (en) 1977-12-01 1979-06-02 Welsh Nat School Med APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES
US4474985A (en) 1981-07-06 1984-10-02 Monsanto Company Purification of N-acetyl aminophenols
JPS5888334A (en) 1981-11-20 1983-05-26 Takasago Corp 3-l-menthoxypropane-1,2-diol
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
GB8629567D0 (en) 1986-12-10 1987-01-21 Boots Co Plc Therapeutic agents
US4883660A (en) * 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5196486A (en) 1989-03-17 1993-03-23 Nalco Chemical Company Alkoxylated vinyl polymer demulsifiers
US5100898A (en) 1990-01-25 1992-03-31 Richardson-Vicks Inc. Antitussive liquid compositions containing dyclonine
SK42593A3 (en) * 1990-10-31 1993-09-09 Procter & Gamble Antitusic agents
US5196436A (en) 1990-10-31 1993-03-23 The Procter & Gamble Company Dextromethorphan antitussive compositions
CZ210496A3 (en) 1994-01-24 1996-12-11 Procter & Gamble Method improving solution process of difficult-to dissolve pharmaceutically active compounds
US5510389A (en) 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5846557A (en) * 1996-03-20 1998-12-08 Cumberland Packing Corporation Chewing gum containing cough suppressing agent
DE69732412T2 (en) 1996-04-12 2006-01-05 Novadel Pharma Inc. BUKALES, POLAR SPRAY
US5955098A (en) 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
SE9601528D0 (en) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as an antitissue agent
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
AU7916798A (en) 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
AU4894697A (en) 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295941A2 (en) * 1987-06-19 1988-12-21 ELAN CORPORATION, Plc Liquid suspension for oral administration
WO1993000072A1 (en) * 1991-06-27 1993-01-07 Richardson Vicks, Inc. Process for solubilizing difficultly soluble pharmaceutical actives
WO1994018970A1 (en) * 1993-02-18 1994-09-01 Warner-Lambert Company Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents
WO1995004527A1 (en) * 1993-08-05 1995-02-16 R.P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution

Also Published As

Publication number Publication date
AU762366B2 (en) 2003-06-26
CN1336823A (en) 2002-02-20
HUP0105021A2 (en) 2002-05-29
US20030139437A1 (en) 2003-07-24
NO20013442L (en) 2001-09-11
KR20010093255A (en) 2001-10-27
WO2000041693A2 (en) 2000-07-20
JP2002534463A (en) 2002-10-15
AU2962700A (en) 2000-08-01
CZ20012491A3 (en) 2001-12-12
EP1140093A2 (en) 2001-10-10
CN1203854C (en) 2005-06-01
CA2356881A1 (en) 2000-07-20
KR100511730B1 (en) 2005-08-31
BR0007445A (en) 2001-10-16
US6846495B2 (en) 2005-01-25
CO5270007A1 (en) 2003-04-30
PE20001415A1 (en) 2001-01-05
TR200101927T2 (en) 2001-11-21
NO20013442D0 (en) 2001-07-11
HUP0105021A3 (en) 2003-02-28
CA2356881C (en) 2012-02-28

Similar Documents

Publication Publication Date Title
WO2000041693A3 (en) Compositions having improved delivery of actives
WO2000041692A3 (en) Compositions having improved stability
WO2004054542A3 (en) Oral drug delivery system comprising high viscosity liquid carrier materials
HUP0202797A2 (en) Compositions having improved stability
HUP0105005A3 (en) Device for dosing the administration of an injectable product
WO2005032474A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
HUP0700086A2 (en) 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
ES2193726T3 (en) MEDICINAL AEROSOL FORMULATIONS.
WO2002060385A3 (en) Pharmaceutical formulation
WO2001041737A3 (en) Solid oral dosage form
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
WO2005016423A3 (en) Delivery devices
AU9680201A (en) Anhydrous dentifrice formulations for the delivery of incompatible ingredients
EE200200522A (en) The enzyme-cleaving peptide conjugated to the active ingredient, a pharmaceutical composition containing it and its use as an antitumor drug
HK1083200A1 (en) Pharmaceutical preparations for oral administration, containing ion- exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents
AP2005003382A0 (en) Liquid pharmaceutical formulations of palonosetron.
WO2002017855A3 (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
IL174655A0 (en) Drug containing (2r)-2-propyloctanoic acid as the active ingredient
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
WO2006102990A3 (en) Tablet containing steroid hormones
WO2000041694A3 (en) Compositions having improved stability
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
MXPA05009601A (en) Dispensing devices.
ZA200203077B (en) Ciclesonide contained pharmaceutical composition for application to mucosa.
HUP0301590A3 (en) Nonpeptide substituted spirobenzoazepines as vasopressin antagonists, pharmaceutical compositions containing them and their preparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00802692.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2356881

Country of ref document: CA

Ref document number: 2356881

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/01927

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 593304

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00600/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 29627/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007015

Country of ref document: MX

Ref document number: PV2001-2491

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020017008796

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000908243

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000908243

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017008796

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-2491

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 29627/00

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017008796

Country of ref document: KR